vida: extract claims from 2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap

- Source: inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md
- Domain: health
- Claims: 1, Entities: 1
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation.md

@@ -1,20 +0,0 @@
----
-type: claim
-domain: health
-description: "Omada's high-touch program shows 63% of members maintaining or continuing weight loss 12 months after GLP-1 discontinuation, with 0.8% average weight change versus 6-7% regain in unassisted cessation"
-confidence: experimental
-source: Omada Health internal analysis (n=1,124), presented ObesityWeek 2025, not peer-reviewed
-created: 2026-04-13
-title: Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
-agent: vida
-scope: causal
-sourcer: Omada Health
----
-
-# Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement
-
-The prevailing evidence from STEP 4 and other cessation trials shows that GLP-1 benefits revert within 1-2 years of stopping medication, suggesting continuous delivery is required. However, Omada Health's Enhanced GLP-1 Care Track analysis challenges this categorical claim. Among 1,124 members who discontinued GLP-1s, 63% maintained or continued losing weight 12 months post-cessation, with an average weight change of just 0.8% compared to the 6-7% average regain seen in unassisted cessation. This represents a dramatic divergence from expected rebound patterns.
-
-The program combines high-touch care teams, dose titration education, side effect management, nutrition guidance, exercise specialists for muscle preservation, and access barrier navigation. Members who persisted through 24 weeks achieved 12.1% body weight loss versus 7.4% for discontinuers (64% relative increase), and 12-month persisters averaged 18.4% weight loss versus 11.9% in real-world comparators.
-
-Critical methodological limitations constrain interpretation: this is an observational internal analysis with survivorship bias (sample includes only patients who remained in Omada after stopping GLP-1s, not population-representative), lacks peer review, and has no randomized control condition. The finding requires independent replication. However, if validated, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes by establishing sustainable behavioral patterns during the medication window.

entities/health/omada-health.md

@@ -1,12 +0,0 @@
-# Omada Health
-
-**Type:** Digital health company  
-**Focus:** Employer-sponsored chronic condition management programs  
-**Key Product:** Enhanced GLP-1 Care Track with behavioral wraparound
-
-## Overview
-Omada Health operates digital health programs for chronic condition management, primarily distributed through employer-sponsored benefits. Their Enhanced GLP-1 Care Track combines medication support with high-touch behavioral interventions including care teams, dose titration education, side effect management, nutrition guidance, exercise specialists, and access barrier navigation.
-
-## Timeline
-- **2025-01-01** — Internal analysis (n=1,124) shows 94% GLP-1 persistence at 12 weeks vs. 42-80% industry range, and 63% of discontinuers maintaining or continuing weight loss 12 months post-cessation
-- **2025-10-XX** — Presented post-discontinuation outcomes at ObesityWeek 2025 (peer-reviewed publication pending as of April 2026)

inbox/queue/2026-04-13-uspstf-2018-b-recommendation-glp1-pharmacotherapy-gap.md

@@ -7,12 +7,9 @@ date: 2018-09-18
 domain: health
 secondary_domains: []
 format: report
-status: processed
+status: unprocessed
-processed_by: vida
-processed_date: 2026-04-13
 priority: high
 tags: [uspstf, glp1, policy, obesity, aca-coverage, pharmacotherapy, access-infrastructure]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/queue/2026-04-13-wasden-2026-racial-disparities-glp1-prescribing.md

@@ -7,12 +7,9 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: processed
+status: unprocessed
-processed_by: vida
-processed_date: 2026-04-13
 priority: high
 tags: [glp1, racial-disparities, access-equity, medicaid, prescribing-disparities, health-equity]
-extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content